<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04950764</url>
  </required_header>
  <id_info>
    <org_study_id>CB8025-21838</org_study_id>
    <nct_id>NCT04950764</nct_id>
  </id_info>
  <brief_title>An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)</brief_title>
  <official_title>The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CymaBay Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CymaBay Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study&#xD;
      Following Oral Dosing of Seladelpar to Subjects with Primary Biliary Cholangitis (PBC) and&#xD;
      Hepatic Impairment (HI)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Seladelpar 10 mg</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate maximum concentration (Cmax) of seladelpar and metabolites</measure>
    <time_frame>17 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the time take to reach Cmax (Tmax) of seladelpar and metabolites</measure>
    <time_frame>17 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate area under the concentration curve versus time curve of seladelpar and metabolites</measure>
    <time_frame>17 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the amount of seladelpar excreted in the urine (Ae)</measure>
    <time_frame>17 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate safety and tolerability as assessed by the incidence of treatment emergent adverse events and serious treatment emergent adverse events across child pugh treatment groups</measure>
    <time_frame>17 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Primary Biliary Cholangitis</condition>
  <condition>Compensated Cirrhosis</condition>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Seladelpar 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: Single oral dose 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seladelpar 10 mg or less</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B: Multiple oral dose of 10 mg or less</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seladelpar 10 mg</intervention_name>
    <description>Seladelpar 10 mg single oral dose</description>
    <arm_group_label>Seladelpar 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seladelpar 10 mg or less</intervention_name>
    <description>Seladelpar 10 mg or less, once daily for 28 days</description>
    <arm_group_label>Seladelpar 10 mg or less</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females between 18 and 80 years of age (inclusive) who are able to&#xD;
             comprehend instructions and follow the study procedures and are willing to sign an&#xD;
             Informed Consent Form (ICF)&#xD;
&#xD;
          2. Females of childbearing potential who are sexually active with a non-sterile male&#xD;
             partner (sterile male partners are defined as men vasectomized since at least 6&#xD;
             months) must be willing to use the contraceptive methods throughout the study and for&#xD;
             30 days after study drug administration.&#xD;
&#xD;
          3. For at least 90 days after study drug administration, non-vasectomized males must not&#xD;
             donate sperm, be willing to use contraception with childbearing potential partners and&#xD;
             any male subject with a pregnant partner must use a condom.&#xD;
&#xD;
          4. Willing to abstain from consuming grapefruit, pomelo, star fruit, or Seville orange&#xD;
             containing products from 7 days prior to dose of study medication through day of&#xD;
             discharge.&#xD;
&#xD;
          5. Confirmed diagnosis of PBC with evidence of cirrhosis and Child-Pugh classification of&#xD;
             CP-A, CP-B or CP-C&#xD;
&#xD;
          6. Screening laboratory parameters:&#xD;
&#xD;
               -  ALP, ALT and AST &lt; 10 × ULN&#xD;
&#xD;
               -  Total bilirubin ≤ 5 × ULN&#xD;
&#xD;
          7. Ursodeoxycholic acid (UDCA) for a minimum of 12 weeks of treatment prior to Day 1&#xD;
&#xD;
          8. At screening confirmed diagnosis of PBC&#xD;
&#xD;
          9. MELD-Na scores of 6 to 24&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant or history of acute or chronic liver disease of an etiology&#xD;
             other than PBC&#xD;
&#xD;
          2. Patients with a diagnosis of overlapping PBC and autoimmune hepatitis&#xD;
&#xD;
          3. History, evidence, or high suspicion of hepatobiliary malignancy based on imaging,&#xD;
             screening laboratory values, and/or clinical symptoms.&#xD;
&#xD;
          4. Presumptive or diagnosed infection that requires systemic therapy within 12 weeks of&#xD;
             Screening and through Day 1&#xD;
&#xD;
          5. Female subjects who are pregnant or nursing&#xD;
&#xD;
          6. Screening ECG that demonstrates a QT interval ≥ 500 msec, or any other significant ECG&#xD;
             finding with clinically significant abnormalities as determined by the Investigator&#xD;
&#xD;
          7. Positive for HBsAg, HCV RNA, or anti HIV antibody&#xD;
&#xD;
          8. Any non-hepatic acute or chronic condition that, in the opinion of the Investigator,&#xD;
             would limit the patient's ability to complete and/or participate in the study or&#xD;
             compromise the integrity of the data&#xD;
&#xD;
          9. Has experienced an illness that is considered by the Investigator to be clinically&#xD;
             significant within 2 weeks before administration of investigational product&#xD;
&#xD;
         10. Clinically relevant drug or alcohol abuse within 6 months of Screening. A positive&#xD;
             drug screen will exclude subjects unless it can be explained by a prescribed&#xD;
             medication&#xD;
&#xD;
         11. Use of obeticholic acid (OCA), any drug of the same class, or fibrates (e.g.,&#xD;
             bezafibrate, fenofibrate, elafibranor, lanifibranor, pemafibrate, saroglitizar) within&#xD;
             30 days of Baseline&#xD;
&#xD;
         12. Use of an experimental or unapproved treatment for PBC within 30 days of Baseline&#xD;
&#xD;
         13. Clinically evident complication(s) of cirrhosis and portal hypertension that required&#xD;
             either emergency room visit, hospital admission or both during the 12 week period&#xD;
             prior to investigational product administration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elaine Watkins, DO, MSPH</last_name>
    <phone>510-293-8800</phone>
    <email>ewatkins@cymabay.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>American Research Corporation at the Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>210-253-3426</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PBC</keyword>
  <keyword>Primary Biliary Cholangitis (PBC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seladelpar</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

